0001193125-24-000300.txt : 20240102 0001193125-24-000300.hdr.sgml : 20240102 20240102090335 ACCESSION NUMBER: 0001193125-24-000300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 24500496 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 8-K 1 d678133d8k.htm 8-K 8-K
Scilex Holding Co false 0001820190 0001820190 2024-01-02 2024-01-02 0001820190 sclx:CommonStockParValue0.0001PerShare2Member 2024-01-02 2024-01-02 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member 2024-01-02 2024-01-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 2, 2024

 

 

SCILEX HOLDING COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39852
   92-1062542
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

960 San Antonio Road, Palo Alto, California, 94303

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (650) 516-4310

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   SCLX   The Nasdaq Stock Market LLC
Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share   SCLXW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the fiscal year ended December 31, 2023 based on currently available information. The Company’s independent auditor has not reviewed or audited these preliminary estimated financial results. The Company’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. The Company has not fully completed its review of these preliminary financial results for the fiscal year ended December 31, 2023. The Company estimates that:

 

  •  

ZTlido gross sales for the fiscal year ended December 31, 2023 were in the range of $145.0 million to $150.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 51% to 56%.

 

  •  

ZTlido net sales for the fiscal year ended December 31, 2023 were in the range of $46.0 million to $52.0 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 21% to 37%.

 

  •  

Total product gross sales for the fiscal year ended December 31, 2023 were in the range of $150.0 million to $155.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 56% to 61%.

 

  •  

Total product net sales for the fiscal year ended December 31, 2023 were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.

On January 2, 2024, the Company issued a press release that included certain preliminary unaudited financial results for the twelve months ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 2.02 by reference.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

99.1    Press Release, dated January 2, 2024.
104    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SCILEX HOLDING COMPANY
By:  

/s/ Jaisim Shah

Name:   Jaisim Shah
Title:   Chief Executive Officer & President

Date: January 2, 2024

 

3

EX-99.1 2 d678133dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO     

 

FOR IMMEDIATE RELEASE

     January 2, 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

PALO ALTO, CA. January 2, 2024 /Newswire/ — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for the fiscal year ended December 31, 2023, based on currently available information.

The Company estimates that:

 

  •  

ZTlido gross sales for the fiscal year ended December 31, 2023 were in the range of $145.0 million to $150.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 51% to 56%.

 

  •  

ZTlido net sales for the fiscal year ended December 31, 2023 were in the range of $46.0 million to $52.0 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 21% to 37%.

 

  •  

Total product gross sales for the fiscal year ended December 31, 2023 were in the range of $150.0 million to $155.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 56% to 61%.

 

  •  

Total product net sales for the fiscal year ended December 31, 2023 were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.

This preliminary financial data has been prepared by and is the responsibility of Scilex. Scilex has not fully completed its review of these preliminary financial results for the fiscal year ended December 31, 2023. Scilex’s independent auditor has not reviewed or audited these preliminary estimated financial results. Scilex’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.

 

Page | 1

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and reached agreement on a path forward to file an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica) with the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product ZTlido® in October 2018, in-licensed a commercial product Gloperba® in June 2022, and launched its third FDA-approved product Elyxyb® in April 2023. It is also developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex in-licensed the exclusive rights to commercialize Elyxyb® (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex launched Elyxyb® in April 2023, and is planning to commercialize Gloperba® by 2024, and is well-positioned to market and distribute those products. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2 study, triple-strength formulation of ZTlido®, for the treatment of chronic neck pain, with FDA Fast Track status. We received our SP-103 Phase 2 top-line results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of SP-103 in acute low back pain associated with muscle spasms. SP-103 was safe and well-tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. We will continue to analyze the SP-103 Phase 2 trial data along with a recently completed investigator study of ZTlido in patients with chronic neck pain which also has showed promising top-line efficacy and safety results. Scilex is planning to initiate Phase 2/3 trial in chronic neck pain in 2024; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and is expected to initiate Phase 2 trials in 2024.

Scilex Holding Company is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform

 

Page | 2

Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the Company’s preliminary unaudited financial results for the fiscal year ended December 31, 2023, the potential impact of the successful FDA audit on Scilex’s commercialization plans for ZTlido®, Scilex’s plans to initiate a Phase 2/3 trial in chronic neck pain in 2024 and plans to initiate Phase 2 trials in 2024 for SP-104, Scilex’s belief that it is well positioned to continue its growth over the next several years, Scilex’s long-term objectives and commercialization plans, Scilex’s potential to attract new capital, future opportunities for Scilex, Scilex’s future business strategies, the expected cash resources of Scilex and the expected uses thereof; Scilex’s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido®, Gloperba®, ELYXYB®, SP-102 (SEMDEXA™), SP-103 or SP-104, if approved by the FDA; Scilex’s development and commercialization plans; and Scilex’s products, technologies and prospects.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: the risk that Scilex’s actual unaudited financial results for the fiscal year ended December 31, 2023 may differ from those set forth in this press release; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials for SP-102, SP-103 or SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media

Scilex Holding Company

960 San Antonio Road

Palo Alto, CA 94303

Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

 

Page | 3

# # #

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2023 Scilex Holding Company All Rights Reserved.

 

Page | 4

EX-101.SCH 3 sclx-20240102.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 sclx-20240102_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sclx-20240102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Par Value 0.0001 Per Share 2 [Member] Common Stock Par Value 0.0001 Per Share 2 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] EX-101.PRE 6 sclx-20240102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g678133g1231000103871.jpg GRAPHIC begin 644 g678133g1231000103871.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#VGQ%XBL?# M.EM?7SG&=L<:_>D;T%<)"/'?C>/[7'=+HFF2N1\Q^N0/2LK7Y_\ MA+?BY:Z3,2UE:R^5L[':-S_F01^ KV4 *H50 , #M7.KU9/71'H22PL(Z7G M)7UZ(\?U'P-XYTM#=6&O7%X4Y*QW+JY_ G!_.H?#WQ4U33;D6?B&)KB)6VM) MLVRQ_4=#].#[U[!=7EM8P&>ZGC@B'5Y&"BO*_&&H^"-8OUN76]EN%&UWLU5! M)Z;BP[>H%9U(^SUA*QU86H\5[E6GS+NEL>IV-]:ZE9QW=G,LT$HRKJ>#_P#7 M]JL5XSH'C71_"_FI8:?J+02XW1RW*LH/J!MX-=GIGQ/\.Z@ZQS3264A_Y^%P MO_?0R/SQ6L*\)+5ZG)7R^M3;<8MK^NQV=%-CDCFC62)U>-AE64Y!'L:=6YP! M113)9HH$WS2I&O\ >=@!^M #Z*H?VYI&[;_:MCGT^T)_C5R*:*=-\,J2+_>1 M@1^E #Z*** "BF2S10)OED2-1_$[ "J9US2 VTZK8@^GVA/\: +]%10W,%RN MZ">.5?6-PP_2I: "BHY)X8B!)*B9Z;F IS.BIO9E"CG<3Q0 ZBF1RQRC,U M "T5$ES!(VV.:-V]%<$T)=6\DSPQSQ-*GWD5P67ZB@"6BBB@#P+2;H6/Q=>> M9L#^TID8G_:9E_K7IWBSQU;:"6L[0+<:ACE<_+%_O>_M7E_Q TU],\<7C %4 MN&%Q&1WW=?\ Q[-:S6?_ F%DFI62!M6B 2\@7K+V$J_U]Z\Y5)PYH1W/IWA MJ-9TZU3X;6_ROY&+?ZA?ZS^']K9*EQJ@6XN.HB_@3Z_WC^E=JJJBA44*H& , 4Z>%E+WJC'BF<=R3T^AKCK#P%XC\4(NHZK?F%91N0SDNY![[>P_$5 M8^+&G7,6MVFJB,O;-$L><9 923@_4'^=;EG\6M&DMU^U6MW#+CYE159<^QR/ MY5T'FE#_ (4ZFS_D--N_Z]^/_0JR;_P+XD\*(VHZ5?&9(AN=H"4< =RO=:?=_U[_\ V5>G@ # & .@I: / M';[X::]HBF]TC4/M#Q_-B+,@5S,/@;2+;Q#_;<+7$=UYIEVJXV9.<\8Z,=5ET7PK?7MN=LRJ$C M;^Z6(7/X9S6[7(_$S_D1KS_?C_\ 0Q0!YYX>\"W_ (NL)-4?4D0M*4S("[,1 M@DD_C6M_PIZ\_P"@O!_WZ/\ C4O@/QIHFA>&_L=_?]!>#_OT?\:U_#'PWN= \06VI2:C%,L.[ M*+&03E2/7WK5_P"%F^%_^?R7_OP_^%:VA^*=*\1/,FFSO(T(!?=&5QG..OTI M V]3YIH4'^M_VA_M?S^O5? 'CK^TE31]6DQ?*-L,K'_6^ MQ_VOY_7KZ'7FGC_P,TI?7-'0K<)\\\*<%N^]??U'X]>H!Z4S*BEF("@9))X MKR#QCXNNO%%^N@:"'DMF?8S)UG;_ .)'_P!>LF\\;Z[XATBUT)%+32'RY'C^ M_<>@/I[^M>D^"O!D/AFS\^<+)J4J_O).H0?W5_J>] %?2/!K>'/"MZ+/$FM3 M6[ S+U#8X5#V^O<_IC6T(>]1=/.)/.!LX8P?,AQ(N?-'50$#9SUR0G48 MYS0 4444 >0^*+N/Q=KVIZ0H07UA(?L!'!E"C$D9]3D%A]"*Y'2KZZTJ^2>W MD:&>,]1U'L:O^';3^T?BOY4F<+?RRMS_ '69OYBO1O%_@*/6)&U#3=D-\>70 M\++_ (-[]_UKS73E43FMTSZJEBJ.%E&A4^%K[O\ @,M>'?'-EJJ)!>LMM>=. M3A'/L>WT-=;7SQ#?$6K'5[73HKHO;LWSI+\P5! MRV/3@&KI8IWY9HQQN3TW%UL/*RWMT^3(OB!*K^*[D _<5%/_ 'R#_6N@^%,9 M^PZE-V:5%'X G^M>?>(M5&I:W>72GY9)6*_[N>/TQ7667BR'P'X#SM XK.E)>V327W;GJ%[>6^G64UY=2". M"%"[N>P%>>_"WS-1U#Q#KSH52\N $!^K,1^&Y:X^74?$_P 3=32Q3]W9JV65 M 1%$/[S'N?\ (KVC0M&MM T>WTVT!\N%>6(Y=N['W)KKC+VLU);(\.K26%HN MG)WG*WR11U;Q1X?L[XZ1J _#$S[FTF($_W'91^ M0.*ROB#X,D\0P1WU@!]O@7:4)QYJ=<9]1SCZUR>F_$77?#J+IVKV!G,0VCSL MQR #U..?R_&N@\T[W_A7GA;_ *!8_P"_TG_Q507/PU\,7$3(EF\#$H?%'6=4!M=(T\6\DG 9^"KO3;MM:U=2ETP(BB8Y9<]6;W]O^#V\2V4=Q9[1?VX(0$X$B_P!W M/KZ?CZTP.QSD9%%>-:;X_P!?\,(NFZMIYG$(VJ)LI( .V>X_#\:V1\8;7;SH M\V?3SA_A2 ],KE(O'NG3^)_["AM[B2?SC#YB[=F1U/7.!@UQ>H?$_6=75K/1 M].^SR2?*&0F23\.!@_A6[\/O!-QI$S:OJJ[;QU(BB)R8P>I/N>GY_@ 8_P 8 M/^0CI?\ UR?^8KK_ !5_R36Y_P"O6/\ FMAUX7X:\8WO@J&ZTZ72_, M9I=[+(Q1E. ,=#Z"MW_A<-Q_T!(__ @__$T >KUR/Q,_Y$:\_P!^/_T,5RW_ M N&X_Z D?\ X$'_ .)K?NKBX\=_#>ZEBM1%<2$E(5;=DHP.,\@UY5X[\;2W]P?#^A,TF]O+FEBY,AZ;%QV]3W^G6;Q M[XY=W?0M$>/DDGC8N._8G\*U_ ?@=-!A74-00-J4B\*>1"#V_WO4_ MA]0#C-2^'&J:/H4&JV\S/>1?O)XH^L8Z@J1UQW_2NU\">-TU^!;"^<)J4:]3 MP)@.X]_4?C].VKRCQUX+ETRX/B#0@T:HWF31Q<&(_P!]?;U]/IT /5Z*X_P1 MXUB\1VHM;LK'J<2_,O02C^\O]1784 %%%% 'C%W$/!_QCBO+CY+*[F:19#TQ M("#^3$_A7L]8GB?PQ8^*=,^R78*.AW0S*/FC;^H]17$Q:CXY\$P_8[G3O[9L M(AB*:/)8+V&1DC\1^-7^*UT3P6+JVTF21M1O(O*96<,+>,_>]\D8'/:H-0^(7B_5U-KI> MBRVC-P6CB:23\"1@?E4?A_X6ZMJ=R+SQ!*UM$S;F0ONFD^IYQ]3S[5G4DJCM M!:]SJPU-X97Q$[1_EON9?@?PS-XFU=9)4/\ 9]NP:=ST;_8'N?T'X5Z))\-+ M#4-6FU+6+R>\EE?<8U'EH!V7C)P!@=>U==I^GVFEV4=G90+#!&,*B_S]S[U9 MK2GAXQC9ZG+BFL)72%Y2)0JYW#CM5:X\0+=:OID M-E+,J/*1*K1E=PXQU'UH$:7_ C>A[MW]CV&?^O=/\*NV]G:V@Q;6T,(](XP MO\JS-:1G8HQD@>O-5-2%_X?MAJ":C-=1*X$T4^#D$X M^4]J .EHK$\2WLUKH)N;65HW++AAUP:VA]T?2@".>V@N4V7$,0/F'X_SH Z*:UM[@@SP12D="Z!L?G4@ M Z 5BZ5?2W6O:K'Y_F6\8B,(&, ,N>/K4!FO-8U>\MHKM[.TM"%8Q ;W M8Y[GIT- &Y+:V]P09K>*0CH70'^=1_V98?\ /C;?]^E_PJIHTL;&:./5A?JN M",D%DZ]2.N:U: *O]F6'_/C;?]^E_P *GBBC@39%&D:#^%% %<_%+>Z[J5XD M=[):6=J_E 0X#NPZDD_3]:V+*WGM(9%N+M[D Y1G4!@,=#CK0!)+9VL[;IK: M&1O5T!/ZTS^S+#_GQMO^_2_X5B:<;[Q#$]\VH36L!]6]%O[E[ MV]TV\<2S6A&)@,;U/3(]>GYT :']F6'_ #XVW_?I?\*?'8VD+AXK6!''1EC M(KGH=8NX/%EQ;W#EK%I!"FRVU_IL(O6M()F<2NI Z8QUIV@WT]Q?7U MO]J-Y:P[?+N"H&21R,CK_P#6]Z -^D(!!!&0>H-J/+:G-E8%!2%Y+:;_ )Z8SQ]01_GOMZ8TU_X>A9YW6:6,_O1U!]: -.BN5&L:B8_[ M&P1JV_RS+M^79U\S\O\ /:NCCMRD2(T\KLJ@%B>6]Z )Z*** "BBB@ HHHH M**** ,S4['[5?:=+YFSR)=V-N=W3\NE&I6/VK4=.G\S;]GD+8VYW9Q^72BB@ M!VK:6NHQQNLK07$#;XIE&2I^G<5E1V=UKD@AU"\#VT+9:*.+;YA'J6 MEZL33A5*M#NQ@#WK1TO218R37,L[W-W/CS)6&,X[ =A110 RSL/(U[4+SS=W MGA/DVXVX&.N>:='IZ_VU>W#L'6>)4,97C&,?C110!!HVBQ:1?WQAD+1R[2J$ M?HV$MC=RZG8W(A>4 31O'N5SV/48HHH ?H6G/#/5YY_>PO'N5F]>HQW_.M/3%N?LQDNKGSW MD.X8C"A!Z 444 9$UG31]LQ/V8NS$KS M(S#D]>/UHHH LZEIRWFIZ=.S@+ S$H5SNSC_ K1*B*%A$JI@$@ <#\*** , M.S\+Z>UIF[C^TW$A9GF)*DDGT!J]I-J]MI M'F\WR]R*^W'';OVHHH IQ>'X M)_#,6G3/O,>XI*%P5.2E6]OOW^6F-V,9HHH K#3_^*G;4/-ZV ..WE>7M]\YSFM6BB@#_]D! end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 02, 2024
Document And Entity Information [Line Items]  
Entity Registrant Name Scilex Holding Co
Amendment Flag false
Entity Central Index Key 0001820190
Document Type 8-K
Document Period End Date Jan. 02, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-39852
Entity Tax Identification Number 92-1062542
Entity Address, Address Line One 960 San Antonio Road
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94303
City Area Code (650)
Local Phone Number 516-4310
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Common Stock Par Value 0.0001 Per Share 2 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol SCLX
Security Exchange Name NASDAQ
Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share
Trading Symbol SCLXW
Security Exchange Name NASDAQ
XML 9 d678133d8k_htm.xml IDEA: XBRL DOCUMENT 0001820190 2024-01-02 2024-01-02 0001820190 sclx:CommonStockParValue0.0001PerShare2Member 2024-01-02 2024-01-02 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member 2024-01-02 2024-01-02 Scilex Holding Co false 0001820190 8-K 2024-01-02 DE 001-39852 92-1062542 960 San Antonio Road Palo Alto CA 94303 (650) 516-4310 false false false false Common stock, par value $0.0001 per share SCLX NASDAQ Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share SCLXW NASDAQ true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d678133d8k.htm sclx-20240102.xsd sclx-20240102_def.xml sclx-20240102_lab.xml sclx-20240102_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d678133d8k.htm": { "nsprefix": "sclx", "nsuri": "http://www.vickersvantagecorp.com/20240102", "dts": { "inline": { "local": [ "d678133d8k.htm" ] }, "schema": { "local": [ "sclx-20240102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "sclx-20240102_def.xml" ] }, "labelLink": { "local": [ "sclx-20240102_lab.xml" ] }, "presentationLink": { "local": [ "sclx-20240102_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-01-02_to_2024-01-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d678133d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-01-02_to_2024-01-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d678133d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "sclx_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vickersvantagecorp.com/20240102", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "sclx_CommonStockParValue0.0001PerShare2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vickersvantagecorp.com/20240102", "localname": "CommonStockParValue0.0001PerShare2Member", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock Par Value 0.0001 Per Share 2 [Member]", "terseLabel": "Common Stock Par Value 0.0001 Per Share 2 [Member]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "sclx_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vickersvantagecorp.com/20240102", "localname": "WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]", "terseLabel": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "sclx_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vickersvantagecorp.com/20240102", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vickersvantagecorp.com//20240102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001193125-24-000300-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-000300-xbrl.zip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end